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Abstract To gain insight into the role of prostanoids in human
kidney function, we examined the distribution of cyclooxygenase
(COX) 1 and COX-2 by immunofluorescence and immunohis-
tochemistry in human kidneys from adults of various age groups.
COX-1 was detected in the collecting ducts, thin loops of Henle
and portions of the renal vasculature. COX-2 was detected in the
renal vasculature, medullary interstitial cells, and the macula
densa. In addition, COX-2 immunoreactivity was noted in
afferent arteries and the macula densa of the renal cortex and
was more evident in the kidneys of older adults.
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1. Introduction
The cyclooxygenase enzymes (COX) catalyze the formation
of prostanoids and are the products of two distinct genes,
COX-1 and COX-2. The COX-1 gene is ubiquitous and has
been previously linked to the cytoprotective e¡ects of prosta-
noids in the gut as well as to the gastrointestinal (GI) toxicity
associated with sustained non-steroidal anti-in£ammatory
drug (NSAID) therapy [1,2]. The COX-2 gene is induced by
a variety of stimuli and has been linked to in£ammatory re-
sponses [3^5]. It has been demonstrated that COX-2 selective
inhibitors have anti-in£ammatory activities with a reduced GI
toxicity pro¢le [6^9].
Both COX-1 and COX-2 are expressed in the kidney [10^
14], and sustained NSAID therapy has a low incidence of
renal toxicity [15,16]. Previous reports have stated that
COX-1 is highly expressed in the collecting ducts and the
renal vasculature of rats, dogs, rabbits, monkeys, and humans
[12^14]. However, the renal distribution of COX-2 di¡ers
among these species, in addition to di¡ering from the COX-
2 expression pattern found in humans. Although it has been
shown that COX-2 is expressed in the macula densa of rats,
rabbits and dogs [12^14], this observation has not been re-
ported in humans or non-human primates [10,14]. Moreover,
in rats and dogs, the expression of COX-2 in the macula
densa is positively regulated by volume depletion caused ei-
ther by low salt diet or by angiotensin-converting enzyme
inhibitors [12,14,17]. In humans, these conditions are more
frequent in the elderly who are also more likely to undergo
chronic NSAID therapy. Therefore, we examined the distri-
bution of COX-1 and COX-2 from adults within di¡erent age
groups.
2. Materials and methods
2.1. Sample preparation
Kidney tissues were obtained from 10 patients aged 17^97 years old
(average: 52.5, median: 43, see Table 1). Their deaths were unrelated
to renal or cardiovascular pathologies (mostly car accidents). The
kidneys were ¢xed in paraformaldehyde, dehydrated, embedded in
para⁄n and sectioned onto Superfrost Plus slides (Fisher Scienti¢c,
Pittsburgh, PA, USA). The samples were encoded for unbiased exami-
nation and review.
2.2. Immunohistology
Immunostaining was performed using rabbit polyclonal anti-pep-
tide antisera ovCOX-1 (160108, Cayman Chemical Co., Ann Arbor,
MI, USA), hCOX-2 (160107, Cayman), mCOX-2 (160116, Cayman)
and rabbit antiserum raised against whole ovCOX-2 protein. All steps
were performed at room temperature.
Brie£y, sections were depara⁄nized, hydrated to dH2O, and
washed in PBS. Following a 30 min treatment with 0.05% blocking
bu¡er (NEN Life Science Products, Boston, MA, USA) sections were
incubated for 2 h with COX-speci¢c antisera diluted to working con-
centrations in the blocking bu¡er.
Fluorescent detection of bound COX antibodies was accomplished
by a subsequent 1 h incubation with Alexa 594-conjugated anti-rabbit
IgG (Molecular Probes, Inc., Eugene, OR, USA). Colorimetric dem-
onstration of bound COX antibodies was performed by incubating
the sections for 30 min with peroxidase-conjugated anti-rabbit IgG
(Boehringer Mannheim) after washing in PBS/0.05% Tween. The anti-
rabbit IgG was diluted in 10% Superblock (Pierce) to inhibit non-
speci¢c binding. Sections were developed with Enhanced DAB sub-
strate (Pierce). Endogenous peroxidase activity was quenched prior to
application of the secondary antibody by a 15 min treatment with
Peroxidase Inhibitor (Pierce). The slides were counterstained with
Gill’s hematoxylin (Fisher) and examined on a Zeiss Axiophot £uo-
rescence microscope equipped with a CCD camera. Non-speci¢c sig-
nals were recorded from slides tested with the secondary antibodies.
3. Results
3.1. Cyclooxygenase-1
COX-1 expression in the kidney was primarily con¢ned to
the renal medulla. Strong immunoreactivity was detected in
the collecting duct epithelium (Fig. 1A,B). Less intense stain-
ing was seen in the descending thin loops of Henle (arrows in
Fig. 1A,B) and interstitial cells in the papilla (not shown).
Many of the arcuate arteries also expressed COX-1 that ap-
peared to be con¢ned to the tunica media (Fig. 1CC). This
pattern of COX-1 expression was observed in 10/10 speci-
mens.
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3.2. Cyclooxygenase-2
The expression of COX-2 in human kidneys is shown in
Fig. 1D^K. Each of the COX-2 speci¢c antisera gave similar
staining patterns where, in contrast to COX-1, COX-2 protein
was detected in both the medulla and the cortex. In the cortex,
COX-2 immunoreactivity was identi¢ed in the macula densa
(Fig. 1D), the glomerular a¡erent arteriole (Fig. 1E), podo-
cytes in a subset of glomeruli (Fig. 1F,G), and in a limited
number of thick loops of Henle (Fig. 1H,I). In the medulla, as
with COX-1 expression, COX-2 immunoreactivity was limited
to interstitial cells (Fig. 1J) and the tunica media of arcuate
arteries (Fig. 1K).
The presence of COX-2 in the macula densa was more
evident in kidney specimens obtained from older subjects (Ta-
ble 1). We detected COX-2 immunoreactivity in the macula
densa of ¢ve of ¢ve kidneys (100%) from subjects aged 48
years or greater. Only two of ¢ve kidneys (40%) from subjects
less than 40 years of age showed COX-2 macula densa immu-
noreactivity. COX-2 positive immunostaining was also de-
tected within podocytes of the some glomeruli in six of 10
kidneys (60%) (Table 1).
4. Discussion
This is the ¢rst report of the presence of COX-2 protein in
human macula densa. Previous reports failed to detect COX-2
in this structure [10,14] either because of a lower speci¢c ac-
tivity of the COX-2 antisera used in this case or because their
samples came from donors 6 50 years old [14]. The macula
densa functions as an integral part of the renin-angiotensin
system and is thought to monitor Na and K levels in the
distal tubule lumen. Renin release, triggered by the macula
Fig. 1. COX-1 (A^C) and COX-2 (D^K) immunoprotein in human kidney detected by immuno£uorescence (A, C, E, F, H, J) and immunohis-
tochemistry (B, D, G, I, K). A positive labeling with COX-1 antibodies is detected in collecting ducts (A, B), thin loop of Henle (arrows in A,
B) and arcuate arteries (BV in C). In the cortex, COX-2 immunoreactivity (arrows) was observed in the macula densa (D), a¡erent arteriole
(E), glomerular podocytes (F, G) and a small number of thick ascending loops (H, I). In the medulla, positive COX-2 immunoreactivity was lo-
calized to interstitial cells (J) and arcuate arteries (K). GM: glomerulus; CD: collecting ducts; BV: blood vessels.
Table 1
Distribution of COX-2 protein in human kidney
Subject I.D. Sex Age Pod MD TAL mIC BV
A97-102-N1 M 17 3 3 þ + +
A97-107-O1 M 29 þ + þ + +
A97-116-O1 M 29 þ 3 þ + +
A97-122-N1 M 38 + 3 þ + +
A98-86-N1 M 38 þ þ þ + +
36833 F 48 3 + þ + +
15929 M 67 þ + þ n.d. +
A98-80-O1 M 79 3 + þ + +
A-98-85-O1 F 83 þ + þ + +
A98-56-N1 M 97 3 + þ + +
Pod: podocytes; MD: macula densa; TAL: thick ascending loop;
mIC: medullary interstitial cells; BV: blood vessels.
+: present; þ : present in a subset of cells ; 3 : absent; n.d.: not de-
termined.
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densa, results in the eventual secretion of aldosterone that, in
turn, promotes reabsorption of sodium ions and water from
the glomerular ¢ltrate thereby contributing to the mainte-
nance of plasma volume and blood pressure.
Previous reports have proposed that prostanoids are in-
volved in the regulation of renin release [17^20]. In rats, the
COX-2 protein is expressed in the macula densa and other
distal tubule cells [12,20]. After administration of a selective
COX-2 inhibitor, increases in renal renin mRNA levels are
prevented when those animals are maintained on a low so-
dium diet [19]. Our ¢nding of COX-2 protein in human mac-
ula densa suggests the possibility of a similar mechanism for
the regulation of renal renin release in humans.
It has been observed in rodents that angiotensin converting
enzyme inhibitors and angiotensin antagonists induced the
expression of COX-2 in the macula densa. Since renin secre-
tion decreases with aging [21], it is possible that this reduction
is involved in the COX-2 up-regulation observed in the elderly
subjects.
In conclusion, our results corroborate earlier reports of
COX-1 and COX-2 renal expression [10,12^14]. Moreover,
we extend the current data to include the novel ¢nding of
macula densa COX-2 expression in humans.
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